I 
117TH CONGRESS 
2D SESSION 
H. R. 7121 
To require the Secretary of Health and Human Services to maintain a 
list of the country of origin of all drugs marketed in the United States, 
to ban the use of Federal funds for the purchase of drugs manufactured 
in the People’s Republic of China, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
MARCH 17, 2022 
Mr. GALLAGHER (for himself, Ms. STEFANIK, Ms. CHENEY, Mr. BUDD, Mr. 
VAN DREW, Mrs. HARTZLER, and Mr. POSEY) introduced the following 
bill; which was referred to the Committee on Energy and Commerce, and 
in addition to the Committees on Ways and Means, Veterans’ Affairs, 
and Armed Services, for a period to be subsequently determined by the 
Speaker, in each case for consideration of such provisions as fall within 
the jurisdiction of the committee concerned 
A BILL 
To require the Secretary of Health and Human Services 
to maintain a list of the country of origin of all drugs 
marketed in the United States, to ban the use of Federal 
funds for the purchase of drugs manufactured in the 
People’s Republic of China, and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Protecting our Phar-
maceutical Supply Chain from China Act of 2022’’. 
VerDate Sep 11 2014 
00:08 Mar 22, 2022
Jkt 029200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H7121.IH
H7121
pbinns on DSKJLVW7X2PROD with BILLS
SEC. 2. COUNTRY OF ORIGIN OF DRUGS. 
(a) IN GENERAL.—Subchapter A of chapter V of the 
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 351 
et seq.) is amended by adding at the end the following: 
‘‘SEC. 524B. REGISTRY OF DRUGS PRODUCED OUTSIDE THE 
UNITED STATES. 
‘‘(a) IN GENERAL.—The Secretary shall compile and 
maintain a list of all drugs approved under subsection (c) 
or (j) of section 505 of this Act or licensed under sub-
section (a) or (k) of section 351 of the Public Health Serv-
ice Act, and any active ingredients in such drugs, that— 
‘‘(1) are manufactured outside of the United 
States; and 
‘‘(2) are determined by the Secretary to be crit-
ical to the health and safety of consumers in the 
United States. 
‘‘(b) ADDITIONAL LIST.—In conjunction with the list 
described in subsection (a), the Secretary shall compile 
and maintain a list of drugs included on such list that 
are exclusively produced in, or use active or inactive ingre-
dients produced in, the People’s Republic of China. 
‘‘(c) REQUIREMENT.—The list described in sub-
section (a) shall, with respect to each drug included on 
the list, provide information about the supply chain of the 
drug, including each step in the supply chain that occurs 
prior to importation of the drug into the United States.’’. 
VerDate Sep 11 2014 
00:08 Mar 22, 2022
Jkt 029200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H7121.IH
H7121
pbinns on DSKJLVW7X2PROD with BILLS
(b) FEDERAL HEALTH PROGRAM PURCHASE
OF 
DRUGS.— 
(1) IN GENERAL.—Notwithstanding any other 
provision of law, the Department of Health and 
Human Services, the Department of Veterans Af-
fairs, the Department of Defense, and any other 
Federal health care program (as defined in section 
1128B(f) of the Social Security Act (42 U.S.C. 
1320a–7b(b))), with respect to the purchase of a 
drug by such agency or program, the following shall 
apply: 
(A) Beginning on January 1, 2023, such 
agency or program may purchase only drugs for 
which 60 percent or more of the active pharma-
ceutical ingredients are manufactured in coun-
tries described in paragraph (2). 
(B) Beginning on January 1, 2024, such 
agency or program may purchase only drugs for 
which 100 percent of the active pharmaceutical 
ingredients are manufactured in countries de-
scribed in paragraph (2). 
(2) COUNTRIES DESCRIBED.—The countries de-
scribed in this paragraph are countries— 
(A) other than the People’s Republic of 
China; and 
VerDate Sep 11 2014 
00:08 Mar 22, 2022
Jkt 029200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H7121.IH
H7121
pbinns on DSKJLVW7X2PROD with BILLS
(B) that meet the health and safety stand-
ards of the Food and Drug Administration. 
(3) WAIVERS.—The Secretary of Health and 
Human Services may issue waivers of the require-
ments under paragraph (1) for any agency or pro-
gram that is unable to meet such requirements and 
demonstrates a need for the waiver. No waiver may 
be issued under this paragraph for drugs that are 
purchased on or after January 1, 2026. 
(c) LABELING REQUIREMENT.—Section 502 of the 
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352) 
is amended by adding at the end the following: 
‘‘(gg) If it is a drug and its labeling does not specify 
the country of origin of each active ingredient contained 
in the drug.’’. 
SEC. 3. TEMPORARY 100 PERCENT EXPENSING FOR PHAR-
MACEUTICAL AND MEDICAL DEVICE MANU-
FACTURING PROPERTY. 
(a) IN GENERAL.—For purposes of section 168(k) of 
the Internal Revenue Code of 1986, in the case of any 
qualified pharmaceutical and medical device manufac-
turing property which is placed in service after December 
31, 2019, and before January 1, 2027— 
(1) such property shall be treated as qualified 
property (within the meaning of such section), 
VerDate Sep 11 2014 
00:08 Mar 22, 2022
Jkt 029200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H7121.IH
H7121
pbinns on DSKJLVW7X2PROD with BILLS